Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
Was anyone really backing azathioprine against vitamin R in relapsed ANCA-associated vasculitis? Catch-up on the RCT here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) June 3, 2023
✳️10 tweet #NephJC catch-up ✳️
🌟Let’s recap the RITAZAREM trial - a rematch between Rituximab and Azathioprine as the maintenance agent of choice in relapsed ANCA-associated vasculitis.
🌟Have we witnessed the ultimate triumph of Rituximab? pic.twitter.com/HbFKhe6MKc